Athira Pharma Inc’s recent filing unveils that its Officer Mark James Litton acquired Company’s shares for reported $1.0 on Sep 05 ’24. In the deal valued at $0.00 per share,5,032 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Gengos Andrew sold 1,272 shares, generating $720 in total proceeds. Upon selling the shares at $0.57, the CFO and Chief Business Officer now owns 97,532 shares.
Before that, Lenington Rachel sold 2,525 shares. Athira Pharma Inc shares valued at $1,429 were divested by the COO and CDO at a price of $0.57 per share. As a result of the transaction, Lenington Rachel now holds 20,870 shares, worth roughly $13356.800000000001.
Mizuho downgraded its Athira Pharma Inc [ATHA] rating to a Neutral from a an Outperform in a research note published on September 19, 2024; the price target was decreased to $0.50 from $5. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who decreased its forecast for the stock in early September from “a Buy” to “a Neutral”. JMP Securities also remained covering ATHA and has decreased its forecast on September 04, 2024 with a “Mkt perform” recommendation from previously “Mkt outperform” rating. BTIG Research revised its rating on September 04, 2024. It rated ATHA as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ATHA
On Monday, Athira Pharma Inc [NASDAQ:ATHA] saw its stock jump 5.61% to $0.64. Over the last five days, the stock has gained 31.23%. Athira Pharma Inc shares have fallen nearly -73.67% since the year began. Nevertheless, the stocks have fallen -61.45% over the past one year. While a 52-week high of $4.30 was reached on 02/21/24, a 52-week low of $0.41 was recorded on 09/26/24. SMA at 50 days reached $0.7926, while 200 days put it at $2.3261.
Levels Of Support And Resistance For ATHA Stock
The 24-hour chart illustrates a support level at 0.5785, which if violated will result in even more drops to 0.5171. On the upside, there is a resistance level at 0.6881. A further resistance level may holdings at 0.7363. The Relative Strength Index (RSI) on the 14-day chart is 55.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0671, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 32.73%. Stochastics %K at 44.43% indicates the stock is a holding.
How much short interest is there in Athira Pharma Inc?
A steep rise in short interest was recorded in Athira Pharma Inc stocks on 2024-10-15, dropping by 87448.0 shares to a total of 1.56 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 1.65 million shares. There was a decline of -5.61%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 19, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $22 price target.
